Shitara, Kohei http://orcid.org/0000-0001-5196-3630
Muro, Kei
Watanabe, Jun
Yamazaki, Kentaro
Ohori, Hisatsugu
Shiozawa, Manabu
Takashima, Atsuo
Yokota, Mitsuru
Makiyama, Akitaka
Akazawa, Naoya
Ojima, Hitoshi
Yuasa, Yasuhiro
Miwa, Keisuke
Yasui, Hirofumi
Oki, Eiji http://orcid.org/0000-0002-9763-9366
Sato, Takeo http://orcid.org/0000-0001-8688-7295
Naitoh, Takeshi http://orcid.org/0000-0003-4169-6334
Komatsu, Yoshito http://orcid.org/0000-0002-1570-6802
Kato, Takeshi
Mori, Ikuo
Yamanaka, Kazunori
Hihara, Masamitsu
Soeda, Junpei http://orcid.org/0000-0003-3753-0999
Misumi, Toshihiro
Yamamoto, Kouji
Yamashita, Riu
Akagi, Kiwamu
Ochiai, Atsushi
Uetake, Hiroyuki
Tsuchihara, Katsuya http://orcid.org/0000-0001-7507-2349
Yoshino, Takayuki http://orcid.org/0000-0002-0489-4756
Funding for this research was provided by:
This study is funded by Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
Article History
Received: 29 September 2023
Accepted: 21 December 2023
First Online: 12 February 2024
Competing interests
: K.S.: Personal fees for consulting and advisory role from Bristol-Myers Squibb, Takeda, Ono Pharmaceutical, Novartis, Daiichi Sankyo, Amgen, Boehringer Ingelheim, Merck Pharmaceutical, Astellas, Guardant Health Japan, Janssen, AstraZeneca, Zymeworks Biopharmaceuticals, ALX Oncology and Bayer; honoraria from Bristol-Myers Squibb, Ono Pharmaceutical, Janssen, Eli Lilly, Astellas and AstraZeneca; research funding (all to institution) from Astellas, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Chugai, Merck Pharmaceutical, Amgen, Eisai, PRA Health Sciences and Syneos Health, outside of the submitted work. K. Muro: Consulting and advisory role for Chugai Pharma, AstraZeneca, Ono Pharmaceutical and Amgen; honoraria from Chugai Pharma, Ono Pharmaceutical, Takeda, Eli Lilly, Bayer, Sanofi, Bristol-Myers Squibb and Taiho Pharmaceutical; research grant from Taiho Pharmaceutical, Astellas Pharma, Amgen Astellas Biopharma, (rest to institution) Merck Sharp & Dohme, Daiichi Sankyo, Shionogi, Kyowa Kirin, Gilead Sciences, Merck Serono, Pfizer, Sanofi, PAREXEL, Mediscience Planning, Sumitomo Dainippon Pharma, Solasia Pharma and Ono Pharmaceutical. J.W.: Speakers bureau for Covidien Japan, Johnson & Johnson/Janssen, Eli Lilly Japan and Takeda; research funding (to institution) from Medtronic, TERUMO and Stryker Japan. K. Yamazaki: Honoraria from Chugai Pharma, Daiichi Sankyo, Yakult Honsha, Takeda, Bayer, Merck Serono, Taiho Pharmaceutical, Eli Lilly, Sanofi, Ono Pharmaceutical, Merck Sharp & Dohme and Bristol-Myers Squibb; research funding (to institution) from Taiho Pharmaceutical. H. Ohori: Honoraria from Daiichi Sankyo, Yakult Honsha, Takeda, Taiho Pharmaceutical, Eli Lilly, Merck Sharp & Dohme and Bristol-Myers Squibb. N.A., M.Y., H. Ojima, Y.Y., K. Miwa, H.Y., K.A. and A.O. report having no relationships to disclose. A.T.: Grants from Takeda, Ono Pharmaceutical, Merck Sharp & Dohme, Bristol-Myers Squibb, Isofol Medical AB, Hutchison Medipharma, Incyte Corporation, Pfizer, Daiichi Sankyo; personal fees from Eli Lilly Japan, Taiho Pharmaceutical, Ono Pharmaceutical, Chugai Pharmaceutical, Takeda, Merck Serono and Merck Sharp & Dohme. A.M.: Personal fees from Eli Lilly Japan, Taiho Pharmaceutical, Ono Pharmaceutical, Bristol-Myers Squibb and Daiichi Sankyo. M.S.: Honoraria from Yakult Honsha, Takeda, Merck Serono, Taiho Pharmaceutical, Eli Lilly, Ono Pharmaceutical and Johnson & Johnson. E.O.: Speakers bureau for Chugai Pharma, Eli Lilly Japan, Takeda, Ono Pharmaceutical, Bayer Yakuhin and Bristol-Myers Squibb Japan. T.S.: Consulting and advisory role for Takeda; speakers bureau for Chugai Pharma, Eli Lilly Japan, Taiho Oncology, Takeda, Bayer Yakuhin, Ono Yakuhin and Daiichi Sankyo/UCB Japan. T.N.: Honoraria from Chugai Pharma, Taiho Pharmaceutical, Kaken Pharmaceutical, Daiichi Sankyo, Eli Lilly Japan, Takeda, Merck, Bayer and Boehringer Ingelheim; research funding (all to institution) from Chugai Pharma, Taiho Pharmaceutical, Kaken Pharmaceutical, Daiichi Sankyo and Eli Lilly Japan. Y.K.: Speakers bureau for Ono Pharmaceutical, Taiho, Chugai, Eli Lilly and Bayer Yakuhin; research funding from Ono Pharmaceutical, Taiho, Daiichi Sankyo, Chugai and IQVIA. T.K.: Honoraria from Chugai Pharma, Yakult Honsha, Ono Pharmaceutical, Takeda, Eli Lilly Japan, Taiho Pharmaceutical and Asahi Kasei; research funding from Chugai Pharma. I.M.: Employment with Takeda Pharmaceutical Company Ltd. K. Yamanaka: Employment with Takeda Pharmaceutical Company Ltd. M.H.: Employment with Takeda Pharmaceutical Company Ltd. J.S.: Employment with Takeda Pharmaceutical Company Ltd. T.M.: Honoraria from Chugai Pharma, AstraZeneca and Mivarisan. K. Yamamoto: Honoraria from Chugai Pharma, J-Pharma, Johokiko, Triceps and CMIC Holdings; research funding from Taiho, Boehringer Ingelheim, Takeda, Daiichi Sankyo and Astellas. R.Y.: Honoraria from Chugai Pharma, Takeda and BitBiome; consulting and advisory role for Takeda. H.U.: Speakers bureau for Takeda, Chugai Pharma and Taiho. K.T.: Honoraria from Chugai Pharma, Novartis, Takeda, Miyarisan Pharmaceutical, Bristol-Myers Squibb Japan, AstraZeneca, Illumina, Eisai, Boehringer Ingelheim Seiyaku and Bayer Yakuhin. T.Y.: Honoraria from Chugai Pharma, Merck, Bayer Yakuhin, Ono Pharmaceutical, Takeda, and Merck Sharp & Dohme; consulting and advisory role for Sumitomo Corp.; research funding (all to institution) from Merck Sharp & Dohme, Daiichi Sankyo, Ono Pharmaceutical, Taiho Pharmaceutical, Amgen, Sanofi, Pfizer, Genomedia, Sysmex, Nippon Boehringer Ingelheim, Eisai, FALCO Biosystems, Roche Diagnostics and Chugai Pharma.